(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.79%) $83.19
(-1.16%) $1.619
(-0.40%) $2 337.90
(1.02%) $27.53
(0.65%) $928.10
(-0.17%) $0.933
(-0.12%) $11.01
(-0.23%) $0.799
(0.00%) $92.17
Live Chart Being Loaded With Signals
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease...
Stats | |
---|---|
今日成交量 | 6 874.00 |
平均成交量 | 49 649.00 |
市值 | 4.92M |
EPS | $0 ( 2024-04-02 ) |
下一个收益日期 | ( $0 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.150 |
ATR14 | $0.0710 (1.57%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-08 | Singer William S. | Buy | 800 | Stock Option (Right to Buy) |
2024-04-08 | Silverman Joshua | Buy | 800 | Stock Option (Right to Buy) |
2024-04-08 | Schechter Jonathan | Buy | 800 | Stock Option (Right to Buy) |
2024-04-08 | Bernstein Bruce | Buy | 800 | Stock Option (Right to Buy) |
2023-03-29 | Schechter Jonathan | Buy | 20 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
74.96 |
Last 71 transactions |
Buy: 1 845 200 | Sell: 283 116 |
Synaptogenix, Inc. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-6 347.00 (0.00 %) |
EPS: | $-12.96 |
FY | 2023 |
营收: | $0 |
毛利润: | $-6 347.00 (0.00 %) |
EPS: | $-12.96 |
FY | 2022 |
营收: | $0 |
毛利润: | $-5 714.00 (0.00 %) |
EPS: | $-0.780 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.51 |
Financial Reports:
No articles found.
Synaptogenix, Inc.
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。